[CLVS] Clovis Oncology, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 533.24 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 45.35 Change: 0.32 (0.71%)
Ext. hours: Change: 0 (0%)

chart CLVS

Refresh chart

Strongest Trends Summary For CLVS

CLVS is in the medium-term up 146% in 7 months and down -74% below S&P in 1 year. In the long-term down -94% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements w

Fundamental Ratios
Shares Outstanding38.39 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV2.11 Price/Cash Per Share
Price/Free Cash Flow-4.47 ROA-27.31% ROE-76.19% ROI
Current Ratio7.93 Quick Ratio Long Term Debt/Equity Debt Ratio0.22
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.19 M Cash From Investing Activities-143.03 M Cash From Operating Activities-48.41 M Gross Profit
Net Profit-63.14 M Operating Profit-64.22 M Total Assets704.71 M Total Current Assets441.7 M
Total Current Liabilities55.68 M Total Debt287.5 M Total Liabilities452.12 M Total Revenue
Technical Data
High 52 week32.67 Low 52 week3.12 Last close3.21 Last change2.88%
RSI20.96 Average true range0.29 Beta1.33 Volume1.42 M
Simple moving average 20 days-17.78% Simple moving average 50 days-36.87% Simple moving average 200 days-80.19%
Performance Data
Performance Week1.58% Performance Month-43.19% Performance Quart-73.97% Performance Half-84.87%
Performance Year-87.99% Performance Year-to-date-82.13% Volatility daily3.69% Volatility weekly8.26%
Volatility monthly16.93% Volatility yearly58.65% Relative Volume1318.58% Average Volume3.84 M
New High New Low


2020-05-28 08:00:00 | Clovis Oncology Announces New Recommendations for Rubraca® rucaparib Tablets in Updated National Comprehensive Cancer Network NCCN Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer mCRPC

2020-05-21 16:10:00 | Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program

2020-05-21 14:24:29 | Clovis Oncology Needs a Savior

2020-05-19 18:53:20 | 8 Biotechs Tapping Secondary Markets for $3 Billion

2020-05-19 15:09:19 | Why Clovis Oncology's Stock Is Trading Lower Today

2020-05-18 20:05:00 | Clovis Oncology Announces Pricing of Public Offering of Common Stock

2020-05-18 16:02:00 | Clovis Oncology Announces Proposed Offering of Common Stock

2020-05-18 11:45:03 | Clovis' CLVS Rubraca Gets FDA Approval for Prostate Cancer

2020-05-16 11:31:00 | Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer

2020-05-15 14:30:00 | Rubraca® Rucaparib Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer mCRPC Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy

2020-05-14 10:18:02 | Is Clovis Oncology CLVS Stock a Solid Choice Right Now?

2020-05-11 11:00:00 | Why Clovis Oncology Stock Marched Higher in April

2020-05-06 11:17:03 | Clovis CLVS Q1 Earnings and Revenues Surpass Estimates

2020-05-06 11:10:00 | Edited Transcript of CLVS earnings conference call or presentation 5-May-20 8:30pm GMT

2020-05-06 11:02:43 | Clovis Oncology CLVS Q1 2020 Earnings Call Transcript

2020-05-06 08:02:42 | Benzinga Pro's Top 5 Stocks To Watch for Wed., May 6, 2020: SNY, GRUB, CLVS, NTDOY, FDS

2020-05-05 19:05:11 | Clovis Oncology CLVS Reports Q1 Loss, Tops Revenue Estimates

2020-05-05 16:05:00 | Clovis Oncology Announces First Quarter 2020 Operating Results

2020-05-03 09:25:12 | Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

2020-04-29 16:05:00 | Clovis Oncology to Present at the Bank of America Health Care Conference 2020

2020-04-28 12:34:04 | Will Clovis Oncology CLVS Report Negative Earnings Next Week? What You Should Know

2020-04-22 09:00:01 | Are Options Traders Betting on a Big Move in Clovis Oncology CLVS Stock?

2020-04-21 16:05:00 | Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5

2020-04-15 12:00:04 | Clovis CLVS Upgraded to Buy: Here's Why

2020-04-14 17:08:00 | Clovis Oncology Announces Debt Exchange Transaction

2020-04-09 10:04:45 | Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca

2020-04-03 17:50:09 | Clovis Oncology CLVS Gains As Market Dips: What You Should Know

2020-03-25 11:30:03 | Why Is Clovis CLVS Down 41.6% Since Last Earnings Report?

2020-03-20 09:36:01 | Is the Options Market Predicting a Spike in Clovis Oncology CLVS Stock?

2020-03-19 17:50:09 | Clovis Oncology CLVS Gains But Lags Market: What You Should Know

2020-03-11 17:50:09 | Clovis Oncology CLVS Stock Moves -1.59%: What You Should Know

2020-03-03 08:30:00 | Clovis Oncology to Present at the Barclays Global Healthcare Conference

2020-03-02 04:00:00 | Clovis Oncology Announces Availability and Reimbursement for Rubraca® rucaparib Tablets for Women with Relapsed Ovarian Cancer in Spain

2020-02-26 09:02:35 | Here's What Analysts Are Forecasting For Clovis Oncology, Inc. After Its Full-Year Results

2020-02-25 10:12:03 | Clovis CLVS Q4 Loss Wider Than Expected, Revenues Beat

2020-02-25 02:06:26 | Edited Transcript of CLVS earnings conference call or presentation 24-Feb-20 9:30pm GMT

2020-02-24 18:15:11 | Clovis Oncology CLVS Reports Q4 Loss, Tops Revenue Estimates

2020-02-24 16:05:00 | Clovis Oncology Announces 2019 Operating Results

2020-02-21 11:30:04 | Is Clovis Oncology CLVS Outperforming Other Medical Stocks This Year?

2020-02-19 10:13:03 | What's in Store for Aimmune AIMT This Earnings Season?

2020-02-19 09:39:02 | Is a Beat in the Cards for Clovis' CLVS Earnings in Q4?

2020-02-19 08:39:01 | Implied Volatility Surging for Clovis Oncology CLVS Stock Options

2020-02-17 12:30:05 | Clovis Oncology CLVS Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2020-02-17 08:46:01 | 5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

2020-02-13 08:30:00 | Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24

2020-02-11 16:05:00 | Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference

2020-02-06 15:34:06 | 4 Stocks Looking Higher During Earnings Season

2020-02-06 11:17:00 | Four stocks to watch this week include Clovis Oncology and 3D Systems

2020-02-03 09:44:02 | Is a Beat in the Cards for Humana's HUM Earnings in Q4?

2020-02-03 04:00:00 | Clovis Oncology Announces Availability and Reimbursement for Rubraca® rucaparib Tablets for Women with Relapsed Ovarian Cancer in France